Literature DB >> 18437037

Utility of a biopsy in suspicious pigmented iris tumors.

Ann Schalenbourg1, Sylvie Uffer, Leonidas Zografos.   

Abstract

BACKGROUND: In the presence of pigmented iris lesions evocative of malignant melanoma and implying oncological treatment, a foregoing biopsy to exclude a benign lesion may seem a reasonable approach. After examining patient files, the utility of such a diagnostic approach was explored.
MATERIAL AND METHODS: Retrospective, consecutive histopathologic case series of 10 pigmented iris tumor specimens excised since 1993. Histopathologic diagnosis was compared with final diagnosis and outcome in the patient's medical chart.
RESULTS: Five biopsies had only nevus cells, whereas ulterior clinical data or histopathologic examinations were compatible with the diagnosis of malignant melanoma. One biopsy contained insufficient sample tissue. Four biopsies confirmed clinical suspicion of iris melanoma.
CONCLUSION: In the current case series, 6 out of 10 biopsies provided a falsely reassuring negative or an inconclusive result. Modern management techniques such as ultrasound biomicroscopy and proton therapy of the whole anterior segment have equally diminished indications for a biopsy. In cases clinically evocative of iris melanoma, a biopsy has only a relative value. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18437037     DOI: 10.1159/000127834

Source DB:  PubMed          Journal:  Ophthalmic Res        ISSN: 0030-3747            Impact factor:   2.892


  2 in total

1.  Multifocal iris melanoma treated with total anterior segment palladium-103 plaque radiation therapy.

Authors:  Vasileois Petousis; Paul T Finger; Tatyana Milman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-12-14       Impact factor: 3.117

2.  Proton beam therapy for presumed and confirmed iris melanomas: a review of 36 cases.

Authors:  Ahmed Rahmi; Hamid Mammar; Juliette Thariat; Gaelle Angellier; Joel Herault; Pierre Chauvel; Laurent Kodjikian; Philippe Denis; Jean Daniel Grange
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-07-20       Impact factor: 3.117

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.